Related Experiment Video
Updated: Feb 6, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble
Massimo Leggio1, Augusto Fusco2, Paolo Severi3,4
1Department of Medicine and Rehabilitation, Cardiac Rehabilitation Operative Unit, San Filippo Neri Hospital, Salus Infirmorum Clinic, Via della Lucchina 41, 00135, Rome, Italy. mleggio@libero.it.
Insights
For patients with atrial fibrillation after percutaneous coronary intervention, dual therapy is often safer than triple therapy. Dropping aspirin in favor of dual therapy with drug-eluting stents may improve net clinical benefit by reducing bleeding risk.
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Pharmacology
Background:
- Managing patients with atrial fibrillation (AF) post-percutaneous coronary intervention (PCI) presents a challenge due to the need for both antiplatelet and anticoagulant therapies.
- Triple therapy (dual antiplatelet therapy and oral anticoagulation) reduces thrombotic events but significantly increases bleeding risk.
- Personalized secondary prevention strategies are crucial to balance ischaemic and bleeding risks for optimal net clinical benefit.
Purpose of the Study:
- To evaluate the optimal antithrombotic strategy for patients with atrial fibrillation undergoing percutaneous coronary intervention.
- To assess the net clinical benefit of dual therapy versus triple therapy in this patient population.
- To provide guidance on the use of non-vitamin K-antagonist oral anticoagulants (NOACs) in contemporary PCI strategies.
Main Methods:
- Review of aggregate evidence from major clinical trials and meta-analyses.
- Analysis of safety profiles of non-vitamin K-antagonist oral anticoagulants and newer drug-eluting stents.
- Comparison of bleeding and ischaemic event rates between dual and triple therapy regimens.
Main Results:
- Contemporary drug-eluting stents and NOACs offer improved safety profiles.
- Dual therapy demonstrates a significantly lower bleeding risk compared to triple therapy.
- Evidence suggests that dropping aspirin in favor of dual therapy with drug-eluting stents may enhance net clinical benefit.
Conclusions:
- Routine full-dose triple therapy should be avoided in patients with AF undergoing PCI outside of clinical trials.
- Utilizing dual therapy, particularly with contemporary drug-eluting stents and NOACs, is a safer strategy.
- Choosing a NOAC as the oral anticoagulant is an effective bleeding avoidance strategy in this high-risk group.
Abstract:
One of the most common conundrums in all cardiovascular medicine pertains to the care of patients with atrial fibrillation after percutaneous coronary intervention, because of both dual antiplatelet therapy and oral anticoagulant therapy would seem to be necessary to reduce risks of stent thrombosis and thromboembolism, respectively, but also with an inevitable trade-off of more bleeding. Patients who require triple therapy are at high risk of both ischaemia and bleeding; therefore, defining a personalised secondary prevention strategy aimed at achieving the best net clinical benefit is essential. The good news is that we have entered an era of increased perceived and tangible safety that applies to both non-vitamin K-antagonist oral anticoagulants and newer drug-eluting stents. Even if the consistency across the major trials and the significantly lower risk of bleeding with dual therapy make it hard to argue that triple therapy should be used routinely, the aggregate evidence suggests that the net clinical benefit of dual therapy should give cardiologists confidence to drop aspirin when they are using a contemporary percutaneous coronary intervention strategy with drug-eluting stents. Waiting for more randomised trials and meta-analyses, for the time being, in patients not in clinical trials, full-dose oral triple therapy with dual antiplatelet agents and full-dose anticoagulation should be avoided as a routine practice, and the choice of the proper, that is, safer, oral anticoagulant, namely a non-vitamin K-antagonist oral anticoagulant, may be regarded by now as an additional bleeding avoiding strategy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Related Concept Videos
03:03Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
03:03Amyloid Fibrils
01:03Nursing Interventions I: Taxonomy of Nursing Interventions
A nursing intervention is a treatment or action based on scientific concepts and knowledge from the nursing, behavioral, and physical sciences. Identifying and prioritizing nursing interventions based on the desired outcome...
01:11Fibril-associated Collagen
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
01:29Nursing Interventions II: Selecting and Classifying the Nursing Interventions
01:06Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....